Display options
Cite
MacDonald D, Prica A, Assouline S, et al. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Curr Oncol. 2016;23(6):407-417doi: 10.3747/co.23.3405.
MacDonald, D., Prica, A., Assouline, S., Christofides, A., Lawrence, T., & Sehn, L. H. (2016). Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Current oncology (Toronto, Ont.), 23(6), 407-417. https://doi.org/10.3747/co.23.3405
MacDonald, D, et al. "Emerging therapies for the treatment of relapsed or refractory follicular lymphoma." Current oncology (Toronto, Ont.) vol. 23,6 (2016): 407-417. doi: https://doi.org/10.3747/co.23.3405
MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Curr Oncol. 2016 Dec;23(6):407-417. doi: 10.3747/co.23.3405. Epub 2016 Dec 21. PMID: 28050137; PMCID: PMC5176374.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2016 Dec;23(6):407-417. doi: 10.3747/co.23.3405. Epub 2016 Dec 21.

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

Current oncology (Toronto, Ont.)

D MacDonald, A Prica, S Assouline, A Christofides, T Lawrence, L H Sehn

Affiliations

  1. Division of Hematology, Dalhousie University, and QEII Health Sciences Centre, Halifax, NS.
  2. Department of Medical Oncology, University of Toronto, and Princess Margaret Hospital, Toronto, ON.
  3. Department of Oncology, McGill University, and Jewish General Hospital, Montreal, QC.
  4. impact Medicom Inc., Toronto, ON.
  5. Hoffmann-La Roche, Mississauga, ON.
  6. Division of Medical Oncology, University of British Columbia, and BC Cancer Agency, Vancouver, BC.

PMID: 28050137 PMCID: PMC5176374 DOI: 10.3747/co.23.3405

Abstract

With no treatment standard having been established for relapsed and refractory follicular lymphoma, a number of therapeutic approaches are used in Canada. In patients who relapse early or who eventually become resistant to subsequent treatment, prognosis is poor, and new approaches are needed. A number of novel therapies are being examined in this setting, including monoclonal antibodies, immunoconjugates, immunomodulatory agents, and signal transduction inhibitors. With the body of evidence for those emerging therapies accumulating and the standard upfront treatment changing from rituximab and chop (cyclophosphamide-doxorubicin-vincristine-prednisone) or rituximab and cvp (cyclophosphamide-vincristine-prednisone) to bendamustine and rituximab, treatment decisions in the relapsed and refractory setting have become more complex. The choice of subsequent treatment must consider type of upfront treatment; duration of remission; and patient-related factors such as age, comorbidities, and treatment preferences. This paper summarizes the evidence for novel therapies and proposes recommendations for subsequent treatment options by remission duration after induction and maintenance.

Keywords: Follicular lymphoma; emerging therapies; novel treatments; refractory disease; relapsed disease

References

  1. Blood. 2008 Jun 15;111(12 ):5486-95 - PubMed
  2. Lancet Oncol. 2016 Jan;17(1):57-66 - PubMed
  3. Blood. 2013 Aug 15;122(7):1137-43 - PubMed
  4. Cancer. 2015 Oct 1;121(19):3465-71 - PubMed
  5. Blood. 2014 May 8;123(19):2944-52 - PubMed
  6. Blood. 2010 Jan 21;115(3):475-80 - PubMed
  7. Blood. 2011 Mar 10;117(10):2807-12 - PubMed
  8. N Engl J Med. 2014 Mar 13;370(11):1008-18 - PubMed
  9. J Clin Oncol. 2011 Sep 1;29(25):3389-95 - PubMed
  10. J Clin Oncol. 2013 Feb 10;31(5):573-83 - PubMed
  11. Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):59-74 - PubMed
  12. Blood. 2012 Apr 19;119(16):3698-704 - PubMed
  13. J Clin Oncol. 2011 Sep 1;29(25):3349-50 - PubMed
  14. Expert Opin Biol Ther. 2016;16(1):57-66 - PubMed
  15. Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):15-8 - PubMed
  16. Lancet Oncol. 2011 Aug;12(8):773-84 - PubMed
  17. J Clin Oncol. 2015 Oct 20;33(30):3467-74 - PubMed
  18. J Clin Oncol. 2005 Feb 1;23(4):667-75 - PubMed
  19. Lancet. 2003 Aug 16;362(9383):516-22 - PubMed
  20. J Clin Oncol. 2005 Feb 1;23(4):676-84 - PubMed
  21. Swiss Med Wkly. 2011 Aug 04;141:w13247 - PubMed
  22. J Clin Oncol. 2015 Aug 10;33(23):2516-22 - PubMed
  23. Blood. 2016 Apr 28;127(17):2093-100 - PubMed
  24. J Clin Oncol. 2013 Aug 10;31(23):2920-6 - PubMed
  25. Br J Haematol. 2014 May;165(3):375-81 - PubMed
  26. J Clin Oncol. 2010 Nov 1;28(31):4740-6 - PubMed
  27. Cancer. 2014 Jan 15;120(2):222-8 - PubMed
  28. Lancet. 2013 Apr 6;381(9873):1203-10 - PubMed
  29. Lancet Oncol. 2016 Aug;17(8):1081-93 - PubMed
  30. J Clin Oncol. 2015 Nov 1;33(31):3635-40 - PubMed
  31. Lancet. 2011 Jan 1;377(9759):42-51 - PubMed

Publication Types